Resources on ASCVD
Atherosclerotic cardiovascular disease (ASCVD) is defined as acute coronary syndromes (ACSs), a history of myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin. AMCP is pleased to work with Medtelligence and Amarin to offer these resources to you, with a specific focus on the use of icosapent ethyl as a treatment for risk reduction.
Using Icosapent Ethyl for Risk Reduction
- Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date. Vascular Health and Risk Management. 2020:16 1-10
- National Lipid Association (NLA) Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High or Very High ASCVD Risk. Journal of Clinical Lipidology. 2019;13(6):860-72.
- Infographic on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High- or Very-high ASCVD Risk
Journal of Managed Care & Specialty Pharmacy (JMCP) Articles on ASCVD
- Change in Proportion of Days Covered for Statins Following Implementation of a Pharmacy Student Adherence Outreach Program. Journal of Managed Care & Specialty Pharmacy, 2019 May;25(5):588-592.
- Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study. Journal of Managed Care & Specialty Pharmacy, 2019 May;25(5):544-554.
- Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms. Journal of Managed Care & Specialty Pharmacy, 2017 Sep;23(9):926-934.